» Articles » PMID: 22589448

Immunopathologic Processes in Sympathetic Ophthalmia As Signified by MicroRNA Profiling

Overview
Specialty Ophthalmology
Date 2012 May 17
PMID 22589448
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Recent discovery of microRNAs and their negative gene regulation have provided new understanding in the pathogenesis of inflammatory diseases. This study demonstrated microRNA expression profiling and their likely role in sympathetic ophthalmia, using formalin-fixed, paraffin embedded samples.

Methods: Two groups of four enucleated globes (total eight globes) from patients with clinical and histopathological diagnosis of SO (experimental samples) and one group of four age-matched, noninflamed enucleated globes (control samples) were used. Human genome-wide microRNA PCR array was performed and results were subjected to bioinformatics calculation and P values stringency tests. The targets were searched using the recently published and periodically updated miRWalk software. Quantitative real-time PCR and immunohistochemical staining were performed to confirm the validated targets in the mRNA and in the protein levels, respectively.

Results: No microRNA was significantly upregulated in SO, but 27 microRNAs were significantly downregulated. Among these, four microRNAs (hsa-miR-1, hsa-let-7e, hsa-miR-9, and hsa-miR-182) were known to be associated with the inflammatory signaling pathway. Only hsa-miR-9 has the validated targets, tumor necrosis factor-α, and nuclear factor kappa B1, which have been previously shown to be associated with mitochondrial oxidative stress-mediated photoreceptor apoptosis in eyes with SO.

Conclusions: Identification of altered levels of microRNAs by microRNA expression profiling may yield new insights into the pathogenesis of SO by disclosing specific microRNA signatures. In the future these may be targeted by synthetic microRNA mimic-based therapeutic strategies.

Citing Articles

Cutting-edge issues in sympathetic ophthalmia approach and six case reports: a T cell-mediated autoimmune response.

Teixeira F, Miguel T, Soares D, Rocha J, Biancardi A, Andrade F Arq Bras Oftalmol. 2024; 87(4):e20220142.

PMID: 38747753 PMC: 11619712. DOI: 10.5935/0004-2749.2022-0142.


MicroRNA-183/96/182 cluster in immunity and autoimmunity.

Wang Z, Dai R, Ahmed S Front Immunol. 2023; 14:1134634.

PMID: 36891312 PMC: 9986322. DOI: 10.3389/fimmu.2023.1134634.


MYC-mediated silencing of miR-181a-5p promotes pathogenic Th17 responses by modulating AKT3-FOXO3 signaling.

Chen S, Ma B, Li X, Zhang K, Wei Y, Du B iScience. 2022; 25(10):105176.

PMID: 36248732 PMC: 9557906. DOI: 10.1016/j.isci.2022.105176.


Sympathetic Ophthalmia: Where Do We Currently Stand on Treatment Strategies?.

Paulbuddhe V, Addya S, Gurnani B, Singh D, Tripathy K, Chawla R Clin Ophthalmol. 2021; 15:4201-4218.

PMID: 34707340 PMC: 8542579. DOI: 10.2147/OPTH.S289688.


MicroRNAs and Autoimmune-Mediated Eye Diseases.

Wei Y, Li N, Zhao L, Yang C, Ma B, Li X Front Cell Dev Biol. 2020; 8:818.

PMID: 32974350 PMC: 7468483. DOI: 10.3389/fcell.2020.00818.


References
1.
Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, Mori L . Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A. 2009; 106(13):5282-7. PMC: 2664036. DOI: 10.1073/pnas.0810909106. View

2.
Furer V, Greenberg J, Attur M, Abramson S, Pillinger M . The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clin Immunol. 2010; 136(1):1-15. DOI: 10.1016/j.clim.2010.02.005. View

3.
MAKLEY Jr T, Azar A . Sympathetic ophthalmia. A long-term follow-up. Arch Ophthalmol. 1978; 96(2):257-62. DOI: 10.1001/archopht.1978.03910050125004. View

4.
ONeill L . Outfoxing Foxo1 with miR-182. Nat Immunol. 2010; 11(11):983-4. DOI: 10.1038/ni1110-983. View

5.
Lindberg R, Hoffmann F, Mehling M, Kuhle J, Kappos L . Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur J Immunol. 2010; 40(3):888-98. DOI: 10.1002/eji.200940032. View